- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02592083
Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors (PREDIX LumA)
PREDIX Luminal A - Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes
Study Overview
Status
Intervention / Treatment
Detailed Description
Pre- or perimenopausal women are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women). Postmenopausal women receive an aromatase inhibitor.This treatment is given for 4 weeks. In cases with uncertain menopausal status (previous hysterectomy and equivocal gonadotropins), postmenopause age limit is defined as 55 years or older.
Ki67 is determined by FNA or core biopsy before start and after 2 weeks of treatment. After the initial 4-week period, patients with signs of response in terms of decrease of Ki67 by ≥20% are randomized to endocrine treatment either alone or in combination with the cdk 4/6 inhibitor palbociclib (arm A and B). Patients with tumors with stable disease, defined as <20% decrease or increase of Ki67 and without radiological indication of tumor progression at the 4-week evaluation are offered continuous endocrine treatment with the addition of palbociclib (arm C).
Dose regimen after 4 weeks of endocrine pretreatment:
Arm A: Pre- or perimenopausal women are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women). Postmenopausal women receive an aromatase inhibitor. The preoperative treatment is continued for further 12 weeks, provided that re-evaluation after 6 and 10 weeks of the preoperative treatment does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option.
Arm B: Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, if re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option.
Arm C: Treatment according to the schedule as described for arm B.
Postoperative chemotherapy is recommended to patients with either residual lymph node metastases >2mm (macro metastases) or primary tumor size >30mm in combination with Ki67>15%. Adjuvant endocrine treatment and radiotherapy is offered according to standard guidelines. Structured follow-up visits yearly for five years include reporting of persistent treatment-related toxicity, HRQoL, recurrence and death.
All patients are recommended adjuvant endocrine treatment for at least 5 years.
The trial contains also a translational subprotocol:
- PET-CT using FDG, confined to the chest, is performed before start of the first treatment period and after 10 weeks, i.e. 6 weeks after treatment allocation (functional imaging, optional).
- Core biopsies from the tumor are collected before start of the first treatment period and after 10 weeks, i.e. 6 weeks after treatment allocation. Further tissue samples are collected from the surgical specimen.
- Blood samples are collected repeatedly during the ongoing treatment and yearly follow-up.
- FNAs from metastases in case of recurrence during follow-up.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 17176
- Department of Oncology, Karolinska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent
- Female patients with non-lobular breast cancer confirmed by histology
- Tumor and blood samples available. Luminal A type confirmed by immunohistochemistry with ER and PR positive ≥50% and the proliferation marker Ki 67 <20% and not HER2 amplified
- Age older than 40 years
- Primary breast cancer >20mm without lymph node metastases
- Adequate bone marrow, renal, hepatic and cardiac functions and no other uncontrolled medical or psychiatric disorders
- LVEF >50%
- ECOG performance status 0-1
Exclusion Criteria:
- Metastases, including node metastases in the ipsilateral and/or contralateral thoracic region or in the mediastinum
- Other malignancy diagnosed within the last five years, except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix
- Age ≤40 years
- Lobular carcinoma
- Patients in child-bearing age without adequate contraception
- Pregnancy or lactation
- Severe medical or psychiatric disorders where the study treatment or study procedures carry increased risk of deterioration of health status
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A: Endocrine treatment
Pre- or perimenopausal women are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor.
The preoperative treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression.
Upon progression (PD), individualized management, preferentially surgery, is the primary option
|
Other Names:
|
Experimental: B: Endocrine treatment + palbociclib
Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period.
The combined treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression.
Upon progression (PD), individualized management, preferentially surgery, is the primary option
|
Other Names:
Other Names:
|
Experimental: C: Endocrine treatment + palbociclib
Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period.
The combined treatment is continued for further 12 weeks, if re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression.
Upon progression (PD), individualized management, preferentially surgery, is the primary option
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical and Radiological Response
Time Frame: After 16 weeks of preoperative treatment
|
Clinical evaluations by use of calliper, radiological evaluations with mammography and ultrasound after 4, 10 and 16 weeks, PET-CT after 10 weeks of treatment, compared with baseline measurements
|
After 16 weeks of preoperative treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological Evaluation of Tumor Response
Time Frame: From date of surgery up to 4 weeks
|
Pathological signs of response, i.e. fibrosis, necrosis aso.
|
From date of surgery up to 4 weeks
|
Disease-free Survival
Time Frame: From date of surgery until 60 months past surgery
|
Disease-free survival includes all events related to breast cancer, and death from any cause during the follow-up period
|
From date of surgery until 60 months past surgery
|
Breast Cancer-specific Survival
Time Frame: From date of surgery until 60 months past surgery
|
Breast cancer-specific survival includes all events related to breast cancer and death caused by breast cancer during the follow-up period
|
From date of surgery until 60 months past surgery
|
Overall Survival
Time Frame: From date of surgery until 60 months past surgery
|
Overall survival relates to death from any cause during the follow-up period
|
From date of surgery until 60 months past surgery
|
Incidence of treatment-emergent adverse events [Safety and Tolerability]
Time Frame: From start of treatment until 28 days after termination of treatment. Delayed toxicity is reported until 60 months follow-up
|
Safety will be assessed using NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE) for reporting laboratory and non-laboratory toxicities.
|
From start of treatment until 28 days after termination of treatment. Delayed toxicity is reported until 60 months follow-up
|
Health-related Quality of Life
Time Frame: From start of study treatment until termination, and then annually during the 60 months of postoperative follow-up period
|
From start of study treatment until termination, and then annually during the 60 months of postoperative follow-up period
|
|
Biological characteristics of tumors exposed to targeted treatment of early breast cancer
Time Frame: Before start and during treatment, at surgery, and then annually during the 60 months of postoperative follow-up period
|
Includes core biopsies and blood samples before start and after 10 weeks of treatment, collection of tumor samples from the surgical specimen at the date of operation, blood samples in connection with annual follow-up visits and FNA and blood samples in case of recurrence.
Time frame for collection of biological samples from start of preoperative treatment until 60 months of follow-up post surgery.
Planned analyses cover genomics (New Generation Sequencing) and proteomics
|
Before start and during treatment, at surgery, and then annually during the 60 months of postoperative follow-up period
|
Immunohistochemical characteristics
Time Frame: Before start, during treatment and at the date of operation
|
Includes core biopsies before start and after 10 weeks of treatment, and collection of tumor samples from the surgical specimen at surgery
|
Before start, during treatment and at the date of operation
|
Thymidine kinase (TK1) activity during study treatment
Time Frame: Before start and until termination of the preoperative treatment
|
Includes repeated blood samples before start and after 4, 10 and 16 weeks of treatment
|
Before start and until termination of the preoperative treatment
|
Drug metabolism during study treatment
Time Frame: Four and ten weeks after start of the preoperative treatment
|
Includes repeated blood samples after 4 and 10 weeks of treatment with the aim to compare intra- and inter-patient metabolism of endocrine treatment in relation to response
|
Four and ten weeks after start of the preoperative treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jonas Bergh, Professor, Dept. of Oncology-Pathology, Karolinska Institutet
- Study Chair: Thomas Hatschek, Assoc. Prof., Breast-sarcoma Unit, Dept. of Oncology, Karolinska University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protein Kinase Inhibitors
- Hormone Antagonists
- Bone Density Conservation Agents
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Palbociclib
- Goserelin
- Tamoxifen
- Exemestane
- Aromatase Inhibitors
Other Study ID Numbers
- PREDIX LumA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early-Stage Breast Carcinoma
-
Cyrcadia HealthStanford University; Ohio State University; SalesforceUnknown
-
Cliniques universitaires Saint-Luc- Université...CompletedObservational Trial on the Impact of Hypnose Used as a Sedation in Oncology Surgery in Breast CancerEarly Stage Breast CarcinomaBelgium
-
Breast Cancer Trials, Australia and New ZealandETOP IBCSG Partners Foundation; Breast International GroupRecruitingEarly Stage Breast CarcinomaTaiwan, Australia, Spain, New Zealand, Ireland, Italy, Argentina, Switzerland, Chile
-
University Hospital Schleswig-HolsteinUniversity of LuebeckActive, not recruitingEarly-Stage Breast CarcinomaGermany
-
European Institute of OncologyActive, not recruitingEarly Stage Breast CarcinomaItaly, Chile, Spain, Switzerland
-
Kliniken Essen-MitteGerman Breast GroupCompletedEarly-Stage Breast CarcinomaGermany, Switzerland
-
University College, LondonUnknownEarly-Stage Breast CarcinomaUnited Kingdom
-
Centre Henri BecquerelUnknownTolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer (EPIC)Early Stage Breast CarcinomaFrance
-
University College, LondonEuropean UnionCompletedEarly-Stage Breast CarcinomaUnited Kingdom, Netherlands, Portugal
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruitingStage 0 Breast Cancer | Cancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Early-Stage Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on Palbociclib
-
PfizerCompleted
-
PfizerCompleted
-
MegalabsNot yet recruiting
-
PfizerCompletedHealthyUnited States
-
Memorial Sloan Kettering Cancer CenterPfizerCompletedSarcoma | LiposarcomaUnited States
-
PfizerCompletedHealthy, Hepatic InsufficiencyUnited States
-
PfizerCompleted
-
PfizerCompleted